Uncommon Cents Investing LLC decreased its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 0.8% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 29,695 shares of the medical equipment provider’s stock after selling 230 shares during the quarter. Zimmer Biomet comprises about 2.3% of Uncommon Cents Investing LLC’s portfolio, making the stock its 14th biggest holding. Uncommon Cents Investing LLC’s holdings in Zimmer Biomet were worth $3,496,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Sound View Wealth Advisors LLC increased its position in shares of Zimmer Biomet by 2.0% during the 1st quarter. Sound View Wealth Advisors LLC now owns 4,456 shares of the medical equipment provider’s stock worth $569,000 after purchasing an additional 87 shares during the last quarter. Advisory Services Network LLC increased its position in shares of Zimmer Biomet by 2.7% during the 4th quarter. Advisory Services Network LLC now owns 3,552 shares of the medical equipment provider’s stock worth $369,000 after purchasing an additional 94 shares during the last quarter. MML Investors Services LLC increased its position in shares of Zimmer Biomet by 3.4% during the 4th quarter. MML Investors Services LLC now owns 2,912 shares of the medical equipment provider’s stock worth $302,000 after purchasing an additional 96 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Zimmer Biomet by 0.9% during the 1st quarter. Louisiana State Employees Retirement System now owns 10,800 shares of the medical equipment provider’s stock worth $1,379,000 after purchasing an additional 100 shares during the last quarter. Finally, Motco increased its position in shares of Zimmer Biomet by 86.2% during the 1st quarter. Motco now owns 216 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 100 shares during the last quarter. 88.60% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently weighed in on ZBH shares. Needham & Company LLC boosted their target price on CoStar Group from $500.00 to $600.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Credit Suisse Group reissued a “market perform” rating and set a $152.00 target price (up from $124.00) on shares of Illinois Tool Works in a report on Monday. Evercore ISI raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 target price on the stock in a report on Monday, April 8th. Sanford C. Bernstein raised Zimmer Biomet from an “underperform” rating to a “market perform” rating and set a $121.71 target price on the stock in a report on Tuesday, June 11th. Finally, Wells Fargo & Co boosted their target price on Zimmer Biomet from $143.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $136.03.

ZBH traded down $0.14 during trading on Monday, hitting $134.36. The stock had a trading volume of 1,035,024 shares, compared to its average volume of 1,192,560. The stock has a 50 day simple moving average of $120.04. The company has a market capitalization of $27.55 billion, a price-to-earnings ratio of 17.59, a price-to-earnings-growth ratio of 2.51 and a beta of 1.14. Zimmer Biomet Holdings Inc has a one year low of $96.99 and a one year high of $136.22. The company has a current ratio of 1.19, a quick ratio of 0.56 and a debt-to-equity ratio of 0.58.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Friday, July 26th. The medical equipment provider reported $1.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.91 by $0.02. The business had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.98 billion. Zimmer Biomet had a positive return on equity of 13.40% and a negative net margin of 4.56%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the previous year, the company posted $1.92 EPS. As a group, sell-side analysts expect that Zimmer Biomet Holdings Inc will post 7.81 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $0.96 annualized dividend and a yield of 0.71%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.57%.

In related news, insider Sang Yi sold 426 shares of the business’s stock in a transaction on Friday, May 24th. The stock was sold at an average price of $114.88, for a total value of $48,938.88. Following the completion of the sale, the insider now directly owns 1,457 shares in the company, valued at approximately $167,380.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.72% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Story: What does earnings per share mean?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.